Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and mortality worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2018)Management of hepatocellular carcinoma J Hepatol 69 182-236

[3] Siegel RL(2020)Hepatitis B virus persistence and reactivation BMJ (Clinical Research Ed) 370 m2200-3715

[4] Laversanne M(2020)Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update J Clin Oncol Off J Am Soc Clin Oncol 38 3698-1313

[5] Soerjomataram I(2017)Hepatitis B cure: from discovery to regulatory approval Hepatology (Baltimore, MD) 66 1296-3216

[6] Jemal A(2021)Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis Cancer Immunol Immunotherapy CII 70 3207-146

[7] Shi Y(2019)Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy Blood 133 137-1599

[8] Zheng M(2021)Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis Cancer Immunol Immunotherapy CII. 7 322-1274

[9] Hwang JP(2019)Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition J Immunother Cancer 20 898-1283

[10] Feld JJ(2021)Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment Clin Gastroenterol Hepatol 67 1560-3496

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and mortality worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2018)Management of hepatocellular carcinoma J Hepatol 69 182-236

[3] Siegel RL(2020)Hepatitis B virus persistence and reactivation BMJ (Clinical Research Ed) 370 m2200-3715

[4] Laversanne M(2020)Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update J Clin Oncol Off J Am Soc Clin Oncol 38 3698-1313

[5] Soerjomataram I(2017)Hepatitis B cure: from discovery to regulatory approval Hepatology (Baltimore, MD) 66 1296-3216

[6] Jemal A(2021)Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis Cancer Immunol Immunotherapy CII 70 3207-146

[7] Shi Y(2019)Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy Blood 133 137-1599

[8] Zheng M(2021)Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis Cancer Immunol Immunotherapy CII. 7 322-1274

[9] Hwang JP(2019)Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition J Immunother Cancer 20 898-1283

[10] Feld JJ(2021)Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment Clin Gastroenterol Hepatol 67 1560-3496